Payment overview · 2025
General Payments
$576.44
32 reported records · 17 companies
Healthcare provider profile · identity verified
Heather Owens, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · GREENWOOD, SC · NPI 1811203482
Verified facts
What the public records show
CMS Open Payments records show Heather Owens, APRN received $576.44 in general payments during 2025 across 32 reported records.
Novo Nordisk Inc accounted for 24.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $143.09 | 24.8% | 9 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $60.53 | 10.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $45.15 | 7.8% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.41 | 6.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.17 | 6.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.61 | 5.7% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $32.00 | 5.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $31.21 | 5.4% | 2 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $21.84 | 3.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.15 | 3.7% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $20.65 | 3.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.50 | 3.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.98 | 3.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.27 | 2.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.70 | 2.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.23 | 2.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $13.95 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $576.44 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $116.63 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $45.15 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $45.15 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $35.41 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $35.17 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $35.17 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $35.17 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $34.31 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $34.05 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.61 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $32.00 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $31.21 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $26.46 | 1 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $26.22 | 1 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.15 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $20.65 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.79 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 239 | 70 |
| Atorvastatin Calcium | Atorvastatin Calcium | 190 | 55 |
| Losartan Potassium | Losartan Potassium | 184 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 171 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 169 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 168 | 44 |
| Potassium Chloride | Potassium Chloride | 122 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 120 | 36 |
| Lisinopril | Lisinopril | 119 | 35 |
| Gabapentin | Gabapentin | 111 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 110 | 34 |
| Metformin Hcl | Metformin Hcl | 104 | 24 |
| Omeprazole | Omeprazole | 104 | 31 |
| Famotidine | Famotidine | 98 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 88 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 16 |
| Furosemide | Furosemide | 71 | 29 |
| Montelukast Sodium | Montelukast Sodium | 62 | 14 |
| Allopurinol | Allopurinol | 60 | 17 |
| Simvastatin | Simvastatin | 59 | 16 |
| Ozempic | Semaglutide | 58 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 57 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 54 | 12 |
| Carvedilol | Carvedilol | 53 | 15 |
| Alendronate Sodium | Alendronate Sodium | 52 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 14 |
| Donepezil Hcl | Donepezil Hcl | 49 | 12 |
| Buspirone Hcl | Buspirone Hcl | 45 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 26 |
| Metformin Hcl Er | Metformin Hcl | 44 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 44 | 13 |
| Eliquis | Apixaban | 43 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Celecoxib | Celecoxib | 42 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 14 |
| Repatha Sureclick | Evolocumab | 39 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Valsartan | Valsartan | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 33 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Cephalexin | Cephalexin | 31 | 28 |
| Memantine Hcl | Memantine Hcl | 30 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | 11 |
| Fluconazole | Fluconazole | 29 | 17 |
| Atenolol | Atenolol | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 27 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 23 |
| Amoxicillin | Amoxicillin | 25 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 23 | 19 |
| Glimepiride | Glimepiride | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Prednisone | Prednisone | 22 | 18 |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 19 |
| Glipizide Er | Glipizide | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Naproxen | Naproxen | 19 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Tramadol Hcl | Tramadol Hcl | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | 12 |
| Trazodone Hcl | Trazodone Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Gemtesa | Vibegron | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $576.44 · 32 records | Novo Nordisk Inc | ABRYSVO, COMIRNATY, Dexcom G6 Transmitter, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, GEMTESA, GVOKE HYPOPEN, JARDIANCE, Kerendia, Korlym, LEQVIO, MOUNJARO, OTEZLA, Ozempic, PREVNAR 20, Paradise Ultrasound Renal Denervation System, REPATHA, Rybelsus, SAPIEN 3 Ultra RESILIA, The Cologuard Plus Collection Kit, UBRELVY, Wegovy, XIFAXAN, XYOSTED, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error